Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ReColorCell is an autologous cell therapy consisting of a suspension of non-cultured melanocytes and keratinocytes. Developed by the Royan Institute and Cell Tech Pharmed, it is designed for the treatment of vitiligo, an autoimmune skin disorder characterized by depigmented patches. The therapy involves harvesting a skin biopsy from the patient, isolating the melanocytes and keratinocytes, and transplanting them back into the patient's depigmented epidermal areas to restore melanin production and skin pigmentation. ReColorCell was approved by the Iranian Food and Drug Administration (IR-FDA) and registered in the Iranian Drug List in December 2021.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ReColorCell.